Form 4: Stoke Therapeutics Chief Medical Officer Reports Stock Transactions

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, acquired 10,000 shares of common stock and 20,000 performance stock units, while also converting 10,000 performance stock units into common stock.

Summary

• Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, engaged in several transactions involving the company's stock on December 3, 2024.
• He acquired 10,000 shares of common stock at a price of $0.
• Additionally, he was granted 20,000 performance stock units, which represent the right to receive one share of common stock each.
• These performance stock units vest in two tranches: half on December 3, 2024, and the remaining half on December 3, 2025, contingent on his continued employment.
• He also converted 10,000 performance stock units into 10,000 shares of common stock.
• Following these transactions, Mr. Ticho directly owns 61,277 shares of common stock and 20,000 performance stock units.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to slightly positive as it aligns management with shareholder interests.

Positives

• The grant of performance stock units to the Chief Medical Officer could be seen as an incentive to align his interests with the company's long-term success.
• The vesting schedule of the performance stock units encourages continued service to the company.

Industry Context

This is a routine filing related to executive compensation and stock ownership, common in the biotechnology industry.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the biotech industry to attract and retain talent.
• Performance-based vesting schedules are also standard to align executive interests with company performance.
• Similar filings are regularly made by executives at comparable companies such as Alnylam Pharmaceuticals and Sarepta Therapeutics.

Stakeholder Impact

• The transactions do not have a direct impact on stakeholders, but the vesting schedule of the performance stock units could be seen as a positive sign of management's commitment to the company's long-term success.

Key Dates

Keywords

Stoke Therapeutics, stock transaction, performance stock units, common stock, insider trading, SEC Form 4, executive compensation, vesting